Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest myelodysplastic syndromes Stories

2013-11-07 08:33:50

BOULDER, Colo., Nov. 7, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that five abstracts were accepted for presentation, including two oral presentations, at the 2013 Annual Meeting of the American Society of Hematology (ASH) on its two wholly-owned hematology drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Ron Squarer, Chief Executive Officer of Array,...

2013-09-12 23:03:32

Insightful research report “Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics” worked out by MP Advisors has been recently published by Market Publishers Ltd. London, UK (PRWEB) September 12, 2013 Recently, cancer treatment has witnessed considerable breakthroughs in terms of the development of innovative drug products. The success in clinical research in this therapeutic area and growth in...

2012-07-01 18:20:20

Findings Could Yield Therapies Against These Serious Blood Diseases and Related Cancers BRONX, N.Y., July 2, 2012 /PRNewswire-USNewswire/ -- Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent...

2011-12-15 14:33:18

Scientists have uncovered a critical genetic mutation in some patients with myelodysplastic syndromes – a group of blood cancers that can progress to a fatal form of leukemia. The research team at Washington University School of Medicine in St. Louis also found evidence that patients with the mutation are more likely to develop acute leukemia. While this finding needs to be confirmed in additional patients, the study raises the prospect that a genetic test could one day more...

2011-12-06 10:00:00

<font size="2" face="Arial"> </font> <font size="2" face="Arial">ROCKVILLE, Md.</font>, Dec. 6, 2011 /PRNewswire/ -- The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is pleased to announce the launch of the Treating MDS Toolkit, a new, free resource developed for health care providers to communicate with and support their patients with myelodysplastic syndromes (MDS). The toolkit was developed in response to the results of an MDS patient...

2010-11-29 14:36:45

Researchers to present 12 oral and 28 poster sessions at the premier hematology research conference The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American Society of Hematology (ASH) Meeting in Orlando from December 4 "“ 6. The presentations showcased at ASH will include 12 oral sessions and 28 poster presentations, including...

2010-04-26 07:00:00

WALTHAM, Mass., April 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene's Vidaza (azacitidine) (seven-day dosing) will retain Decision Resources' proprietary clinical gold standard status through 2013 for the treatment of high-risk myelodysplastic syndromes. While some emerging drugs in development hold promise, none offer significant survival advantages over Vidaza. A modified dosing...

2010-03-11 22:00:00

WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ -- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells. The new outpatient dosing option provides physicians and patients with the flexibility of a dosing regimen with a reduced...

2009-07-08 08:49:00

WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (decitabine for injection) to treat patients with myelodysplastic syndromes (MDS). MDS is a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells....

2009-05-05 07:00:00

The Need for More-Efficacious Treatments Creates Significant Opportunity for Drug Developers in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., May 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2012, growth in the myelodysplastic syndromes drug market will be driven principally by the launch in Europe of Celgene's Vidaza and Revlimid. Launch of...